Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas



Status:Completed
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:September 2012

Use our guide to learn which trials are right for you!

This research is being done to study the safety and utility of 5-aminolevulinic acid (5-ALA)
(also known as Gliolan) for identifying brain tumor tissue during surgery. The goal of this
study is to determine if 5-ALA can differentiate between tumor and normal brain tissue.

Sometimes, during brain surgery, the removal of tumor tissue can be difficult because the
tumor can look like normal brain tissue. Studies in other countries have shown that in some
brain tumors, 5-ALA can make the tumors appear brighter under ultraviolet light. This may
make it easier for doctors to remove as much tumor as safely as possible from your brain.

This study also hopes to see if 5-ALA can find different cell populations within the tumor
that is removed and allow the researchers to better understand brain tumors.

The purpose of this study is to:

- Find out how well 5-ALA can separate normal brain tissue from tumor tissues AND to see
how well 5-ALA can find different cell populations within brain tumors

- Identify the amount of 5-ALA that should be taken before surgery to make the tumors
glow under ultraviolet light

- Make sure the 5-ALA identifies tumor and not normal brain

- Make sure 5-ALA does not cause any side effects


Inclusion Criteria:

- Patients must have clinically documented primary brain tumor for which resection is
clinically indicated. Radiographic findings should be consistent with high grade
glioma. Intraoperative frozen section should either be: anaplastic astrocytoma (WHO
Grade III astrocytoma) or glioblastoma (WHO Grade IV astrocytoma).

- Patients must be aged greater than 18 years old

- Karnofsky Performance Score > 70 (Appendix)

- Patients must have normal organ and marrow function as defined below:

- Leukocytes > 3,000 /uL

- Absolute neutrophil count > 1,500/uL

- Platelets > 100,000/uL

- Total bilirubin within normal institutional limits

- AST/ALT within normal institutional limits

- Creatinine within normal institutional limits

Exclusion Criteria:

- Prior craniotomy for resection, deep seated tumors in thalamus and brain stem.

- History of allergic reactions to compounds of similar chemical composition to ALA.

- Personal or family history of porphyrias

- Personal history of hepatitis or other liver diseases.

- Pregnant women are excluded from this study because ALA is of unknown teratogenic
effects. Because there is an unknown but potential risk for adverse events in nursing
infants secondary to treatment of the mother with ALA, breastfeeding should be
discontinued prior to treatment with ALA.

- Inability to undergo magnetic resonance imaging (i.e. those patients with
AICD/pacemakers).
We found this trial at
2
sites
4940 Eastern Ave
Baltimore, Maryland 21224
(410) 550-0100
Johns Hopkins Bayview Medical Center There is no better story in American medicine in the...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials